---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-001159"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2025-01-03T23:59:59+00:00"
generated_at: "2026-05-28T14:25:36.121926+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics transfers to Nasdaq Capital Market to extend bid price compliance deadline to June 30, 2025

## Summary
- Transfer approved Jan 2, 2025; effective at market open Jan 6, 2025.
- Company failed to regain $1 minimum bid price by original Dec 30, 2024 deadline.
- Additional compliance period until June 30, 2025; must close at $1+ for 10 consecutive business days.
- Bolt may effect a reverse stock split to cure the deficiency if needed.
- Failure to regain compliance by June 30 could lead to delisting and a potential Nasdaq appeal.

## SEC filing metadata
- accession: 0000950170-25-001159
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2025-01-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017025001159/0000950170-25-001159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017025001159/bolt-20250102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-001159
- JSON: https://secwatch.observer/filing/0000950170-25-001159.json
- Plain text: https://secwatch.observer/filing/0000950170-25-001159.txt

## Key facts
- Listing & Compliance Notices
  Bolt Biotherapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: January 2, 2025, the Company received written notice from Nasdaq notifying the Company that its application to transfer the listing of its common stock to The Nasdaq Capital Market was approved. The approval is based upo
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000095017025001159/0000950170-25-001159-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.